Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Roche And KlinRisk Earn CE-Mark For AI Kidney Algorithm As Part Of New Chronic Kidney Disease Panel

Author: Benzinga Newsdesk | October 06, 2025 01:57am

Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function.
This tool will be launched as part of Roche's new chronic kidney disease (CKD) algorithm panel to support care across the stages of the disease which affects 700 million people globally.
Clinicians can use the CKD panel (Kidney Klinrisk Algorithm and Kidney KFRE Algorithm) to evaluate a patient's risk of kidney function decline, including in the early asymptomatic stages of the disease.

Posted In: RHHBF RHHBY RHHVF